Ofatumumab
Products Ofatumumab was approved in 2009 as a concentrate for the preparation of an infusion solution for leukemia treatment (Arzerra). In 2020, a solution for injection was approved in the United States for MS treatment (Kesimpta). Structure and properties Ofatumumab is a human IgG1 monoclonal antibody produced by biotechnological methods. It has a molecular mass … Ofatumumab